

CURRICULUM VITAE

DATE: April 11, 2019

NAME: David Bleich, M.D.

PRESENT TITLE: Chief, Division of Endocrinology, Diabetes, & Metabolism
Program Director, Endocrinology, Diabetes & Metabolism
Professor of Medicine

OFFICE ADDRESS: Division of Endocrinology, Diabetes, & Metabolism
185 South Orange Avenue, MSB I-588
New Jersey Medical School
Rutgers, The State University of New Jersey
Newark, N.J. 07103
Phone: (973) 972-6170
Fax: (973) 972-5185
Mobile: (908) 868-4750
E-mail: bleichda@njms.rutgers.edu

CITIZENSHIP: United States

EDUCATION:

A. Undergraduate
Haverford College 6/1979
Haverford, PA
B.A. Chemistry

B. Professional
New York Medical College 6/1983
Valhalla, NY
Doctor of Medicine

POSTGRADUATE TRAINING:

A. Internship and Residencies
Maimonides Medical Center
Brooklyn, NY
Internal Medicine Internship and Residency
7/1983 to 6/1986

B. Fellowships
Brigham and Women's Hospital/Joslin Diabetes Center
Boston, MA
Endocrinology, Diabetes, & Metabolism Fellowship
7/1987 to 6/1990

MILITARY: None

ACADEMIC APPOINTMENTS:

Department of Medicine
Rutgers New Jersey Medical School (formerly University of Medicine and Dentistry of New Jersey)
Chief, Division of Endocrinology, Diabetes & Metabolism
Professor of Medicine
7/2017 to present

Department of Medicine
Rutgers New Jersey Medical School (formerly University of Medicine and Dentistry of New Jersey)
Chief, Division of Endocrinology, Diabetes & Metabolism
Associate Professor of Medicine
9/2004 to 6/2017

HOSPITAL APPOINTMENTS:

Department of Medicine
Attending Physician
University Hospital, Newark, NJ
9/2004 to present

Department of Diabetes, Endocrinology, & Metabolism
Staff Physician
City of Hope National Medical Center, Duarte, CA
7/1992 to 8/2004

Division of Endocrinology
Consulting Staff
Huntington Memorial Hospital, Pasadena, CA
12/1996 to 8/2004

Emergency Room Physician
Staff Physician
St. Luke's Hospital, New York, NY
10/1986 to 6/1987

OTHER EMPLOYMENT OR MAJOR VISITING APPOINTMENTS:

Medical Science Partners: Obtained venture capital funding and established small laboratory near MIT campus in Cambridge, MA to purify pancreatic islet antigens associated with type 1 diabetes.
08/1990 to 6/1992

PRIVATE PRACTICE

University Physician's Association 2004 to present

LICENSURE:

New Jersey Medical License 25MA07713700 Exp. 06/30/2019
California Medical License G74734; 07/23/1992 to 02/29/2010 (inactive)
Massachusetts Medical License 57450; 04/22/1987 to 02/12/1993 (inactive)
New York Medical License 161181; 01/14/1985 to 12/31/1988 (inactive)

DRUG LICENSURE:

CDS: D08556200 Exp. 10/31/2019
DEA: BB0463721 Exp. 07/31/2019

CERTIFICATION:

American Board of Internal Medicine, Internal Medicine, 110110,
10 September 1986; No Expiration

American Board of Internal Medicine, Endocrinology & Metabolism, 110110,
7 November 1989; No Expiration

MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

2006- present	Foundation for Diabetes Research of New Jersey Grant Review Panel
2009-2010	American Diabetes Association National Study Planning Committee
2011-2013	ADA Medicine, Science and Health Care Awards Committee
2012-2013	American Association of Clinical Endocrinology NJ Chapter Secretary
2013-2014	American Association of Clinical Endocrinology NJ Chapter Treasurer
2014-2016	American Association of Clinical Endocrinology NJ Chapter President
2016-2017	American Association of Clinical Endocrinology NJ Chapter Immediate Past President

HONORS AND AWARDS:

2012 - 2017	Top Doctors New York Metro Area Endocrinology, Diabetes & Metabolism Castle Connolly
2012 – 2016	Inside New Jersey Magazine Top Doctors Endocrinology
2016	Diabetes Physician of the Year, Diabetes Foundation of New Jersey

BOARDS OF DIRECTORS/TRUSTEES POSITIONS:

2015 -	Foundation for Diabetes Research of New Jersey
2017	American Diabetes Association National Board of Directors (approval pending)

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

2005-2007	American Diabetes Association (ADA) Grant Review Panel
2007-2008	American Diabetes Association Grant Review Panel Vice-Chair
2008-2009	American Diabetes Association Grant Review Panel Chair-elect
2009-2011	American Diabetes Association Grant Review Panel Chairman
2012	New Jersey Department of Law & Public Safety - Division of Law Professional Boards Prosecution Section – Advisory Committee to establish guidelines for safe prescribing of anabolic steroids.
2011 /2012	JDRF/American Diabetes Association Genetics of Nephropathy Co-Chair
2012-present	Endocrine Fellows Foundation Grant Review Committee
2011-2013	ADA National Research Policy Committee
2012-2014	ADA Medicine, Science & Healthcare Awards Committee
2014-2016	ADA Medicine, Science, & Healthcare Awards Committee Chairman

2016 Department of Defense: Congressionally Directed Medical Research Program Diabetes 1
Grant Review Panel

SERVICE ON MAJOR COMMITTEES:

Medical School

2004-present Graduate Medical Education Committee
2005-2016 UMDNJ/Rutgers New Jersey Medical School IACUC Member
2009-2012 University Physician Association Board Member
2012-present University Physician Association Finance Committee
2013-present Managed Care Reimbursement Committee
2013-2015 Rutgers New Jersey Medical School Faculty Council
2014-2016 Rutgers Biomedical Health Science Strategic Planning Committee
2014-2015 Rutgers NJMS Curriculum Renewal Committee
2015-2016 Rutgers Robert Wood Johnson Search Committee; Chief of Endocrinology
2016-2017 President-elect Faculty Organization Rutgers NJMS
2017-2018 President, Faculty Organization Rutgers NJMS
2018-2019 Immediate Past President, Faculty Organization Rutgers NJMS

Hospital

2005-2010 Hyperglycemia Management Team
2006- present Faculty Leadership Committee (Previously Faculty Practice Committee)
2013-2014 Readmissions Team Member
2013-2015 ICD-10 Planning Committee

AdHoc Journal Reviewer

Journal of Clinical Endocrinology & Metabolism	2013- present
Diabetes	2006- present
American Journal of Pathology	2008- present
Diabetes Care	2010- present
Cell Transplantation	2012-present
PLOS	2012-present
Cell Biochemistry & Biophysics	2013-present
Pediatric Research	2014
FASEB Journal	2015
Journal of Cellular and Molecular Medicine	2015
Free Radical Biology & Medicine	2016

SERVICE ON GRADUATE SCHOOL COMMITTEES:

2019 Thesis Review Committee for Pamela Hirschberg

SERVICE TO THE COMMUNITY:

American Association of Clinical Endocrinology (AACE) Diabetes Day for Primary Care Providers 2010
American Association of Clinical Endocrinology (AACE) Diabetes Day for Primary Care Providers 2011
Chairman, American Association of Clinical Endocrinology Diabetes Day for Primary Care Providers 2012
Chairman, American Association of Clinical Endocrinology Diabetes Day for Primary Care Providers 2013
Presenter Hot Topics in Internal Medicine 2014
Program Chair, N.J. AACE Annual Symposium 2015

Program Chair, N.J. AACE Annual Symposium 2016
Program Committee N.J. AACE Annual Symposium 2017

SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:

None

SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:

Eric Wwinner	Endocrine Practice, Freehold, NJ	7-01-2003 to 6-30-2005
Swati Sharma	Endocrine Practice, Newark, NJ	7-01-2004 to 6-30-2006
Khushbu Chandarana	Endocrine Practice, North Carolina	7-01-2005 to 6-30-2007
Natalia Anchipolovsky	Endocrine Practice, Hackensack, NJ	7-01-2006 to 6-30-2008
Irene Cho	Endocrine Practice, Westfield, NJ	7-01-2007 to 6-30-2009
Sonia Puthoran	Endocrine Practice, Houston, TX	7-01-2008 to 6-30-2010
Elkin Nunez	Endocrine Practice, Morristown, NJ	7-01-2009 to 6-30-2011
Jennifer Zaitz	Endocrine Practice, Jersey Shore, NJ	7-01-2010 to 6-30-2012
Uzma Shafqat	Endocrine Practice, Montclair, NJ	7-01-2011 to 6-30-2013
Marlyn Fernandez	Endocrine Practice, Hackensack, NJ	7-01-2012 to 6-30-2014
Shira Eytan	Endocrine Practice in Manhattan, N.Y.	7-01-2013 to 6-30-2015
Roopa Roy	Endocrine Practice at St. Peter's Medical Center, New Brunswick, N.J.	7-01-2014 to 6-30-2016
Lena Shalem	Summit Medical Group, Teaneck, N.J.	7-01-2015 to 6-30-2017
Tamara Khaimchakov	M.e.n.d, P.A., Edison N.J.	7-01-2016 to 6-30-2018
Fadwa Sumrein	In-training	7-01-2017 to 6-30-2019

TEACHING RESPONSIBILITIES: (Teaching effectiveness should be addressed in nominating letter)

- A. Lectures or Course Directorships
Rutgers New Jersey Medical School Course Director for Endocrinology 2008-present

CLINICAL RESPONSIBILITIES: (Clinical effectiveness should be addressed in nominating letter)

Doctor's Office Complex (Private Practice) Tuesday & Friday 12 pm to 5 pm
Ambulatory Care Clinic (Public Clinic) Diabetes Clinic Wednesday 8 am to 12 pm
Endocrinology Clinic Thursday 8 am to 12 pm
RVU productivity at 98% benchmark 2016-2017

GRANT SUPPORT: (Please list newest or most current first)

a. Principal Investigator

BAYER PHARMACEUTICAL: FIGARIO STUDY; CVR Mortality in Diabetic Patients
Treated with Fineronone or Placebo 2016-2021 Phase 3 Clinical Trial

FOUNDATION FOR DIABETES RESEARCH OF NEW JERSEY

Reverse Engineering T1D
08-01-2010 through 07-31-2016
Direct Costs: \$ 105,000
Total Costs: \$ 310,000 (with carryover)

FOUNDATION FOR DIABETES RESEARCH OF NEW JERSEY
Curing Type 1 Diabetes with Worms

05-01-2006 through 04-30-2010
Direct costs: \$378,000
Total costs: \$420,000

NIH-R21 DK63351-01
Prevention of Type 1 Diabetes with MMP Inhibitors
10-1-2002 through 7-31-2006 (including one year no-cost extension)
Direct costs: \$614,072
Total costs: \$841,698

JUVENILE DIABETES RESEARCH FOUNDATION 1-2000-565
The Role of Metalloproteinases and Their Inhibitors in Pancreatic β -cell Destruction
9-01-2000 through 8-31-2004 (including one-year no-cost extension)
Direct costs: \$546,500
Total costs: \$605,000

b. Co-Investigator

ROBERT WOOD JOHNSON FOUNDATION (Co-PI)
I-Care 4 Health Transition: Improving Care for a Healthy Transition using a 4-tiered approach to collaboration across the continuum
07-01-2011 through 06-30-2013
Total Costs: \$325,000

INTERNATIONAL DIABETES FEDERATION (Co-PI)
Tailored intervention for inpatients: transitional diabetes care coordinator versus convention care.
09-01-2008 through 08-31-2010
Direct Costs: \$65,000
Total Costs: \$65,000

ALMOND BOARD OF CALIFORNIA (Co-Investigator 7% effort)
The Metabolic Effects of Almond Consumption in Subjects with Pre-Diabetes
01-01-2006 through 12-31-2006
Direct Costs: \$221,000
Total Costs: \$221,000

NIH-DK55240-01 RO1 (P.I. moved to new institution after 1 year)
The Role of Novel Lipid Mediators in Cytokine-induced Pancreatic Islet Dysfunction and Cytotoxicity
10-01-1998 through 9-30-2001
Direct Costs: \$695,940
Total Costs: \$1,029,991

JUVENILE DIABETES RESEARCH FOUNDATION
The Role of Novel Lipid Mediators in Intracellular Signaling, Dysfunction and Cytotoxicity in Cytokine Treated Islets
9-01-1997 through 8-31-1998
Direct Costs: \$175,226
Total Costs: \$196,954

Publications: *(Please list in chronological order; published or accepted for publication only; should be segregated into the following categories)*

- 1 **Bleich D**, Jackson RA, Soeldner S, Eisenbarth GS. Analysis of Metabolic Progression to Type I Diabetes in Islet Cell Antibody Positive Relatives of Patients with Type I Diabetes. Diabetes Care, 13:111-118, 1990.

2. **Bleich D**, Polak M, Eisenbarth GS, Jackson RA. Decreased Risk of Type I Diabetes in Offspring of Mothers Who Acquire Diabetes During Adrenarchy. *Diabetes*, 42:1433-1439, 1993
3. **Bleich D**, Chen S, Gu J-I, Thomas L, Scott S, Gonzales N, Natarajan R, Nadler JL. Interleukin 1- β regulates a leukocyte type of 12-lipoxygenase in rat islet and RIN m5F cells. *Endocrinology*, 136:5736-5744, 1995
4. **Bleich D**, Chen S, Bursten SL, Nadler JL. Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 β -induced dysfunction in cultured rat islets. *Endocrinology*, 137:4871-4877, 1996
5. **Bleich D**, Chen S, Wen Y, Nadler JL. The stress-activated c-jun protein kinase (JNK) is stimulated by lipoxygenase pathway product 12-HETE in RIN m5F cells. *Biochemical and Biophysical Research Communications*, 230:448-451, 1997
6. **Bleich D**, Chen S, Gu J-L, and Nadler J. The role of 12-lipoxygenase in pancreatic β -cells. *International Journal of Molecular Medicine*, 1:265-272, 1998.
7. **Bleich D**, Polak M, Chen S, Swiderik K, Levy-Marchal C. Sera from children with type 1 diabetes react against a new group of antigens composed of lysophospholipids. *Hormone Research*, 52:86-94, 1999.
8. **Bleich D**, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. *Journal of Clinical Investigation*, 103:1431-1436, 1999.
9. Konkal-Matt P, **Bleich D**, Nadler JL. Adeno-associated virus vector mediated gene transfer to non-dividing pancreatic β -cells. *Gene Therapy*, 18:1553-1561, 2000.
10. Han X, Sun Y, Scott S, and **Bleich D**. Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and β -cells. *Diabetes*, 50:1047-1055, 2001.
11. Han X, Chen S, Sun Y, Nadler JL, and **Bleich D**. Induction of cyclooxygenase-2 (COX-2) gene in pancreatic beta cells by 12-lipoxygenase pathway product 12-hydroxyeicosatetraenoic acid (12-HETE). *Molecular Endocrinology*, 16:2145-2154, 2002.
12. Yang F and **Bleich D**. Transcriptional Regulation of Cyclooxygenase-2 Gene in Pancreatic β -cells. *Journal of Biological Chemistry* 279(34):35403-11, 2004.
13. Woods CC, Sundar K, Tessler C, Lebsack TW, Grainger L, Nielsen A, **Bleich D**, and DeLuca D. Tissue Inhibitor of Metalloproteinase-2 Inhibits T-cell Infiltration and Preserves Pancreatic β -cell Function in an *In Vitro* Type 1 Diabetes Mellitus Model. *Journal of Autoimmunity*. 27:28-37, 2006. **(Please note Dr. Bleich and Dr. DeLuca are co-senior authors).**
14. Cohen J, Sundar K, and **Bleich D**. Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking. *Current Immunological Reviews* 3:87-100, 2007.
15. Nemeth ZH, **Bleich D**, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN, Hasko G. Adenosine receptor activation ameliorates type 1 diabetes. *FASEB Journal*. 21: 2379-2388, 2007
16. Liu Q, Mishra PK, Sundar K, Mousavi G, Liu Z, Gaydo A, Alem F, Lagunoff D, **Bleich D**, Gause WC. Helminth infection can reduce insulinitis and type 1 diabetes through CD25- and IL10-independent mechanisms. *Infection and Immunity*. 12:5347-5358, 2009 **(Please note Dr. Bleich and Dr. Gause are co-senior authors).**

17. **Bleich D.** Umbilical Cord Blood and Type 1 Diabetes: A Road Ahead or Dead End? *Diabetes Care* 32:2138-2139, 2009.
18. Wien M, **Bleich D**, Raghuwanshi M, Gould-Forgerite S, Gomes J, Monahan-Couch, Oda K. Almond consumption and cardiovascular risk factors in adults with prediabetes. *J Am Coll Nutr.* 29(3):189-97, 2010.
19. Liu Z, Liu Q, **Bleich D**, Salgame P, Gause WC. Regulation of type 1 diabetes, tuberculosis, and asthma by parasites. *Journal of Molecular Medicine* 88:27-38, 2010.
20. Scollan-Koliopolous M, Walker EA, **Bleich D**. Perceived risk of amputation, emotions, and foot self-care among adults with type 2 diabetes. *The Diabetes Educator* 36:473-482, 2010.
21. Scollan-Koliopoulos M and **Bleich D**. The evaluation and management of childhood type 2 diabetes mellitus. *Primary Care Diabetes* 5:151-158, 2011.
22. Wu G, Liu Z-H, Yuan Z, Gabius H-J, Ledeen RW, **Bleich D** Ganglioside GM1 Deficiency in Effector T Cells from NOD Mice Induces Resistance to Regulatory T Cell Suppression. *Diabetes.* 60:2341-2349, 2011.
23. Ledeen RW, Wu G, Andre S, **Bleich D**, Huet G, Kaltner H, Kopitz J, Gabius H-J. Beyond glycoproteins as galectin counterreceptors: effector T cell growth control of tumors via ganglioside GM1. *Ann. N.Y. Acad. Sci.* 1253:206-221, 2012.
24. Scollan-Koliopolous M, Rapp K.J., **Bleich D**. Afrocentric Cultural Values and Beliefs: Movement Beyond the Race and Ethnic Proxy to Understand Views of Diabetes. *The Diabetes Educator* 38:488-498, 2012.
25. Mishra PK, Patel N, Wu W, **Bleich D**, Gause WC. Prevention of type 1 diabetes through infection with an intestinal parasite requires IL-10 in the absence of a Th2-type response. *Mucosal Immunity* 6:297-308, 2013. **(Please note Dr. Bleich and Dr. Gause are co-senior authors).**
26. Scollan-Koliopoulos M, **Bleich D**, Rapp KJ, Wong P, Hofmann CJ, Raghuwanshi M. Health-related quality of life, disease severity, and anticipated trajectory of diabetes. *Diabetes Educator* 39:83-91, 2013.
27. Zhua Y, You W, Wang H, Li Y, Qiao N, Zhang C, **Bleich D**, and Han X. MicroRNA-24/MODY gene regulatory pathway mediates pancreatic beta-cell dysfunction. *Diabetes* 62:194-206, 2013
28. Mishra PK, Palma M, **Bleich D**, Loke P, Gause WC. Systemic impact of intestinal helminth infections. *Mucosal Immunology* 7(4):753-762, 2014.
29. Eytan S, Kim K-Y, **Bleich D**, Raghuwanshi M, Eloy J.A., Liu, J.K. Isolated double pituitary adenomas: A silent corticotroph adenoma and a microprolactinoma. *J. Clinical Neuroscience* 2015 22(10): 1676-1678.
30. Streb G and **Bleich D**. Calcimimetic Treatment of Remnant Hyperparathyroidism after Near-Total Parathyroidectomy. *Acta Endocrinologica* 2015 11:524-528.
31. Chen F, Sha M, Liu J, Wang Y, Wu T, Shan W, Zhou W, Zhu Y, Sun Y, **Bleich D**, Han X. Transcription factor Ets-1 links glucotoxicity to pancreatic β -cell dysfunction through inhibiting PDX-1 expression in rodent models. *Diabetologia* 2016 59(2):316-324.
32. Jiexin Zhang, Tijun Wu, Shanshan Zhan, Nan Qiao, Xu Zhang, Yunxia Zhu, Nan Yang, Yujie Sun, Xin Zhang, **David Bleich**, and Xiao Han. TIMP-1 and CD82, a promising combined evaluation marker for PDAC. *Oncotarget* 2017 8 (4): 6496-6512.

33. **Bleich D** and Wagner DH. Challenges to Reshape the Future of Type 1 Diabetes Research. Journal of Clinical Endocrinology & Metabolism. 2018. 103(8):2838-2842.

Books, Monographs, and Chapters

Bleich D. Insulin Secretion and Insulin Action. Educational Review Manual in Endocrinology, Diabetes and Metabolism Vol. 2, Diabetes 2006.

Bleich D. The Diabetes LIFEMAP: Transforming Diabetes Care for the 21st Century. Morgan James Publisher. 2019.

Patents Held

Inhibition of Inflammation via Inhibition of COX-2 Gene Transcription

US Patent: 6,469,063

Date of Issue: 22 October 2002

Inventors: David Bleich, Xiao Han, Songyuan Chen

Use of Adeno-Associated Virus (AAV) to Deliver Genes

US Patent: 6,485,976

Date of Issue: 26 November 2002

Inventors: Jerry L. Nadler, David Bleich, Prasad Konkall-Matt

Copyrights Held

The Diabetes LIFEMAP
Rutgers University
RU Docket No. 2018-040

Abstracts

1. **Bleich D.** An Adult with a Pediatric Disease, Medical Times; July 1986.
2. **Bleich D.,** Jackson, R.A., Eisenbarth, G.S. Prodromal Linear Rise of Blood Glucose in Pre-Type I Diabetics, Diabetes; May 1988; Vol 37:4A
3. **Bleich D,** Dotta F., Eisenbarth, G.S., Nayak, R.C. Isolation of an Autoantigenic Monosialoganglioside from Human Pancreas, Clinical Research; Vol 37 #2, 446A April 1989
4. **Bleich D.,** Eisenbarth GS, Jackson RA. Equal Prevalence of Autoantibodies in Offspring of Diabetic Mothers and Fathers, Clinical Research; Vol 38 #2, 355A April 1990
5. **Bleich D.,** Polak, M., Eisenbarth, G.S., Jackson, R.A. Increased risk of diabetes and diabetes related autoantibodies in siblings of families with two Type I diabetic members, Diabetes; May 1991; Vol 40:143A
6. Polak, M., **Bleich, D.,** Eisenbarth, G.S., Jackson, R.A. Occurrence of maternal Type I diabetes after age 13 decreases the transmission rate of disease to offspring. 8th International Beilinson Symposium on Prediabetes. Herzliya. The Journal of Pediatric Endocrinology, Vol 4 #3, Oct. 1991 #57.
7. **Bleich, D.,** Chen, S., Nadler, J.L. Lisofylline prevents IL-1 β induced dysfunction of cultured rat islets. Journal of Investigative Medicine. 1995 Vol 43, Supp. 2:323A.

8. Lev-Ran, A., Yerushalmy, Y., Weissglas, L., Schindel, B., Weinstein, R., **Bleich, D.**, and Nadler, J.L. Diabetes sharply increases coronary morbidity in thyroxine-treated hypothyroid patients. *Israel Journal of Medical Science*. 1997; Vol. 33:1 (Suppl. 1) S-2 Abstract.
9. **Bleich, D.**, Oddenino, C., Gonzales, N., Chen, S., and Nadler, J.L. H7, a protein serine-threonine kinase inhibitor, prevents IL-1 β induced inhibition of DNA synthesis in RIN m5F cells through a nitric oxide-independent mechanism. *Diabetes*; 1997; Abstract #1466.
10. **Bleich, D.**, Chen, S., Funk, C.D., Sun, D., Nadler, J.L. 12-lipoxygenase gene knockout prevents low dose streptozotocin (STZ)-induced diabetes and cytokine-induced islet dysfunction in mice. Presidential Poster Session, 1998 ADA Meeting, Chicago, IL.
11. Konkal-Matt, P., **Bleich, D.**, Nadler, J.L. Adeno-associated virus mediated gene delivery to non-dividing pancreatic beta cells. (*American Society of Gene Therapy* 3/99).
12. Han, X., Nadler, J.L., **Bleich, D.** Evidence that 12-lipoxygenase knockout mice show reduced Th1 cytokine response to low-dose streptozotocin. *Diabetes* 1999 48(Suppl. 1):A429.
13. Konkal-Matt, P., **Bleich, D.**, Nadler, J.L. Novel method of gene delivery to pancreatic beta cells. *Diabetes* 1999 48(Suppl. 1):A58.
14. Yang, F. and **Bleich, D.** Transcriptional Regulation of Cyclooxygenase-2 Gene in Pancreatic β -cells. *Diabetes* 2004.
15. Sundar K, Liu Q, Alem F, Gause WC, and **Bleich D.** 2006. Immunomodulation of type 1 diabetes by parasitic helminths. *Immunology of Infectious Diseases*, Newark, NJ.
16. Cho I and **Bleich D** 2008 A Case of Recurrent Pituitary Apoplexy. P3-792. Endocrine Society Meeting, Chicago, IL.
17. Mishra PK, Yuan Z, Patel N, Gause WC, **Bleich D** 2010 Prevention of type 1 diabetes with a helminth infection is IL-4 independent. P-1353 American Diabetes Association Scientific Sessions, Orlando, FL.
18. Puthooran S, Ertel NH, Raghuwanshi M, Jordan M, **Bleich D.** 2010 Remission of ACTH-independent Macronodular Adrenal Hyperplasia (AIMAH) by Unilateral Adrenalectomy. P-3 676. Endocrine Society, San Francisco, CA.
19. Shafqat U, Raghuwanshi M, **Bleich D**, Ertel N, Liu J. Complex Management of DDAVP Resistant Diabetes Insipidus After Removal of a Third Ventricle Tumor: Importance of Correcting Anterior Hypopituitarism. 2012 American Association of Clinical Endocrinology Annual Meeting, Philadelphia, PA Oral Presentation.
20. Shafqat U, **Bleich D**, Raghuwanshi M. Follicular Thyroid Cancer Presenting as an Autonomous Functioning Thyroid Nodule. 2012 Endocrine Society Poster Presentation
21. Shafqat U, Bleich D, Raghuwanshi M. Granulomatous Hypercalcemia Due to Silicone Implants: Successful Treatment with Denosumab. 2013 Endocrine Society Poster.
22. Fernandez M, **Bleich D**, Liu, JK, Cohen E, Ciminello F, Razdan D, Raghuwanshi M. Metastatic Micro-Papillary Thyroid Cancer to Bone, An Unusual Case. 2013. Endocrine Society Poster Presentation
23. Eytan S, Raghuwanshi M, and **Bleich D.** "An Unusual Case of Bilateral Pituitary Adenoma" Poster presentation at: Endo Society 2015 97th Annual Meeting, San Diego, CA, March 5, 2015

24. Eytan S, Raghuwanshi M, **Bleich D**. “Follicular Thyroid Cancer Presenting as Massive Skull Metastasis” Poster Presentation at: Endo Society 2015 97th Annual Meeting, San Diego, CA, March 6, 2015, winner of Outstanding Abstract Award, also presented at Rutgers Research Day 2015.
25. A rare case of Hashimoto’s Encephalopathy presenting with myoclonus and cognitive impairment. Roy R, **Bleich D**, Raghuwanshi, M, Aleksic S. Poster presentation at International Thyroid Congress 2015
26. Roy R, **Bleich D**, and Raghuwanshi M. A case of rapidly growing adrenal mass and hyperpigmentation caused by disseminated tuberculosis. Poster presentation AACE 25th Annual Conference 2016
27. Singer-Granick CJ, Shalem L, Liu JK, **Bleich D**. Cyclic Cushing’s Disease in an Adolescent with Type 1 Diabetes. Poster Presentation Endocrine Society 99th Annual Meeting Orlando, Fl. April 1, 2017
28. Shalem L, **Bleich D**, Raghuwanshi M. Hypogonadism in Mauriac Syndrome. Poster Presentation Endocrine Society 99th Annual Meeting Orlando, Fl. April 1, 2017
29. Khutorsky T and **Bleich D**. A Case of Fibrous Variant of Hashimoto’s Thyroiditis. Poster Presentation Endocrine Society 99th Annual Meeting Orlando, Fl. April,1 2017.

PRESENTATIONS:

A. Scientific (*Basic Science*):

11-08-2014 Nanjing, China Nanjing International Symposium on Autoimmune Diseases: Curing Type 1 diabetes with Helminth Infection

09-15-2014 Joslin Diabetes Center, Boston, MA; Metabolic Syndrome: Clinical and Molecular Aspects of the “Good Life”

10-08-2010 University of Michigan From Mice to Men and Back Again: Can Helminth Infection Cure Type 1 Diabetes

B. Professional (*Clinical*):

06-22-2016 Rutgers New Jersey Medical School Anesthesiology Grand Rounds: Adrenal Insufficiency in Acute and Chronic Illness

06-15-2016 Eastern Virginia Medical College Medical Grand Rounds: Metabolic Syndrome: Clinical and Molecular Aspects of the “Good Life”.

04-15-2016 Rutgers New Jersey Medical School Pediatrics Grand Rounds: Metabolic Syndrome: A 21st Century Perspective

03-04-2016 American College of Physicians N.J. Chapter: Treating Type 2 Diabetes

11-16-2015 Rutgers NJMS OB/Gyn Grand Rounds: Metabolic Syndrome: A 21st Century Perspective

5-29-2015 Rutgers NJMS Pediatric Grand Rounds: Metabolic Syndrome in Pediatrics

1-20-2015 Rutgers NJMS Medical Grand Rounds: Metabolic Syndrome A 21st Century Perspective
9-27-2014 Rutgers New Jersey Medical School “Hot Topics in Internal Medicine” Improving the Management of Diabetes and its Complications

04-10-2014 Newark Beth Israel Medical Center; Metabolic Syndrome: Clinical and Molecular Aspects of the “Good Life”

03-20-2013 St. Joseph’s Regional Medical Center; Current Concepts in the Management of Diabetic Retinopathy

06-01-2012 Christ Hospital, Jersey City, NJ Adrenal Insufficiency in Acute and Chronic Illness

04-21-2012 Pituitary Education Day, Newark, NJ Introduction to the Pituitary Gland/ Diagnosis of Pituitary Disorders

12-01-2011 Essex County Hospital Center; Treating Type 2 Diabetes in the 21st Century: New Strategies and Targets

10-08-2010 University of Michigan Treating Type 2 Diabetes in the 21st Century: New Strategies and Targets

07-29-2010 Trinitas Medical Center, Elizabeth, NJ Treating Type 2 Diabetes in the 21st Century: New Strategies and Targets

5-8-2010 AACE Endocrine Day for Primary Care Providers

10-27-2009 Metabolic Syndrome: Clinical and Molecular Aspects of the “Good Life” Medical Grand Rounds NJMS

09-09-2009 Mount Vernon Hospital, Mount Veronon, NY Is Pre-Diabetes and Metabolic Syndrome the Same Disease

4-2009 Mountainside Hospital, NJ “Osteoporosis 2009”

03-11-2009 Louisiana State University “Treating Type 2 Diabetes in the 21st Century: New Strategies and Targets

12-14-2007 Oral Health Pavilion of New Jersey Dental School UMDNJ 2007 Research Symposium on Diabetes: Session Chair for *Hyperglycemia, hyperlipidemia, and tissue signaling: Too much of a good thing.*

12-11-2007 Treating Diabetes in the 21st Century: New Strategies and Targets, Medical Grand Rounds NJMS

01-11-2006 NJMS ENT Grand Rounds “Graves Disease”

06-11-2006 Rational Therapeutics Conference, City of Hope National Medical Center, Duarte, CA

11-09-2005 AACE Meeting “How Many Times Can We Cure Type 1 Diabetes”

06-12-2005 Rational Therapeutics Conference, City of Hope National Medical Center, Duarte, CA

05-17-2005 Treating Diabetes in the 21st Century: New Strategies and Targets, Medical Grand Rounds NJMS

3-2005 Mountainside Hospital, NJ "Osteoporosis 2005"

3-2004 Riverside Transplantation Symposium, Ca. Complications of Diabetic Patients with Chronic Kidney Disease

3-2002 Riverside Transplantation Symposium, Ca. Complications of Diabetic Patients with Chronic Kidney Disease